Prognostic and clinical implication of a disintegrin and metalloprotease 8 expression in pediatric medulloblastoma

Expression of a disintegrin and metalloprotease 8 and endostatin in human osteosarcoma: Implication in tumor progression and prognosis

“…Accumulating evidence has demonstrated ADAM8 overexpression in a variety of human tumors [9][10][11][12]23]. The current study identified abundant ADAM8 expression in osteosarcoma and osteosarcoma derived lung metastases.…”

“…Multivariate analysis confirmed that high ADAM8 expression was an independent predictor for poor OS. Recently, the association of ADAM8 up-regulation with aggressive tumor features as well as poor patients' prognosis has also been determined by several studies [9][10][11][12]23].…”

“…The expression pattern of ADAM8 was heterogenous. Therefore, the immunoreactivity score for ADAM8 was based on two parameters: the proportion of positive cells and the intensity of immunoreactivity according to previous studies [10,23]. The number of positive-staining cells showing immunoreactivity in ten representative random microscopic fields was counted and the percentage of positive cells was calculated.…”

“…Its expression was detected under several pathological conditions characterized by inflammation and extracellular matrix remodeling, including cancer [7]. Upregulation of ADAM8 has been reported in different types of cancers including prostate, breast, hepatocellular carcinomas and pediatric medulloblastoma [9][10][11][12].…”

Upregulation of a disintegrin and metalloprotease 8 is associated with progression and prognosis of patients with gastric cancer

“…[10][11][12] ADAM8, a member of the ADAMs family, was initially reported to play potential roles in inflammatory and allergic processes, 13 and further studies have shown that its overexpression is associated with progression and poor survival in various solid tumors. 12,14,15 ADAM8 has been reported to be an independent indicator of lymph node metastasis in human GC 12 ; however, its precise effects on GC progression and prognosis remain unclear. In this study, we focused on the correlation of ADAM8 expression with clinicopathologic features and overall survival (OS); in addition, the mechanisms implicating this protein in GC progression were studied at the molecular level by in vitro assays.…”